New Delhi, Nov. 11 -- Anti-Cancer Drug Price Cuts have brought substantial financial relief to patients undergoing cancer treatment across India, with revised Maximum Retail Prices (MRPs) covering more than 1,300 pharmaceutical formulations taking effect from November 9, 2026. According to figures released by the Ministry of Chemicals and Fertilisers, reductions in the prices of certain cancer medicines have reached as high as 96.45 per cent, potentially easing the financial burden on thousands of patients and their families.

The price revisions follow the National Pharmaceutical Pricing Authority's (NPPA) Trade Margin Rationalisation (TMR) initiative, which limits trade margins to 30 per cent for 137 identified non-scheduled anti-cancer...